LINC01022

Across TCGA pan-cancer cohorts, LINC01022 RNA differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of LINC01022’s most consistent transcriptional readouts.

The strongest signal is observed in breast invasive carcinoma (BRCA), where LINC01022 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types LINC01022 is over-expressed in tumor, although a few such as COAD and ESCA show the opposite, repressed pattern.

BRCA, COAD, and PRAD are the cancer types where LINC01022 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LINC01022 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BRCA	Female	All	+0.168	<.001	6	view →
COAD	All	All	−0.169	.008	4	view →
PRAD	All	All	+0.375	<.001	2	view →
ESCA	Male	All	−0.318	.011	2	view →
LUAD	All	All	+0.141	.034	1	view →
HNSC	All	All	−0.050	.048	1	view →
THCA	All	All	−0.011	.042	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

LINC01022–BRCA

Open the BRCA breakdown →